Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28510986 | 0.80 | MEN1 (0.44) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| SCHEMBL30884950 | 0.78 | LPL (0.34) | CYP11B2P2RX7 | |
| SCHEMBL2428502 | 0.78 | LPL (0.34) | CYP11B2P2RX7 | |
| SCHEMBL20288133 | 0.76 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL28418404 | 0.75 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| SCHEMBL25112078 | 0.74 | MAPK1 (0.33) | P2RX7 | |
| SCHEMBL22122780 | 0.72 | MAPK1 (0.34) | CYP11B2P2RX7 | |
| SCHEMBL16500634 | 0.72 | CHRNB4 (0.55) | CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL12373176 | 0.72 | LPL (0.44) | P2RX7 | |
| SCHEMBL21165502 | 0.71 | P2RX7 (0.33) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10667515-B2 | (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190200611-A1 | (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20180139961-A1 | (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10667515-B2 | (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using | AAAS, NANS, CIAPIN1 | CHRNB2 2259/4885CHRNA4 2648/4885CHRNA7 2246/4885 |
| US-20190200611-A1 | (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING | AAAS, NANS, CIAPIN1 | CHRNB2 2259/4885CHRNA4 2648/4885CHRNA7 2246/4885 |
| US-20180139961-A1 | (S)-5-ETHYNYL-ANABASINE, DERIVATIVES THEREOF, AND RELATED COMPOSITIONS AND METHODS OF MAKING AND USING | AAAS, NANS, CIAPIN1 | CHRNB2 2259/4885CHRNA4 2648/4885CHRNA7 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.